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Summary
 
To examine the role of nuclear factor (NF)-
 
k
 
B in T cell development and activation in vivo,
we produced transgenic mice that express a superinhibitory mutant form of inhibitor 
 
k
 
B-
 
a
 
(I
 
k
 
B-
 
a
 
A32/36
 
) under the control of the T cell–specific CD2 promoter and enhancer (mutant
[m]I
 
k
 
B-
 
a
 
 mice). Thymocyte development proceeded normally in the mI
 
k
 
B-
 
a
 
 mice. How-
 
ever, the numbers of peripheral CD8
 
1
 
 T cells were significantly reduced in these animals. The
mI
 
k
 
B-
 
a
 
 thymocytes displayed a marked proliferative defect and significant reductions in inter-
leukin (IL)-2, IL-3, and granulocyte/macrophage colony-stimulating factor production after
cross-linking of the T cell antigen receptor. Perhaps more unexpectedly, double positive
(CD4
 
1
 
CD8
 
1
 
; DP) thymocytes from the mI
 
k
 
B-
 
a
 
 mice were resistant to 
 
a
 
-CD3–mediated ap-
optosis in vivo. In contrast, they remained sensitive to apoptosis induced by 
 
g
 
-irradiation. Ap-
optosis of wild-type DP thymocytes after in vivo administration of 
 
a
 
-CD3 mAb was preceded
by a significant reduction in the level of expression of the antiapoptotic gene, 
 
bcl-x
 
L
 
. In con-
trast, the DP mI
 
k
 
B-
 
a
 
 thymocytes maintained high level expression of 
 
bcl-x
 
L
 
 after 
 
a
 
-CD3 treat-
ment. Taken together, these results demonstrated important roles for NF-
 
k
 
B in both inducible
cytokine expression and T cell proliferation after TCR engagement. In addition, NF-
 
k
 
B is re-
quired for the 
 
a
 
-CD3–mediated apoptosis of DP thymocytes through a pathway that involves
the regulation of the antiapoptotic gene,
 
 bcl-x
 
L
 
.
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T
 
he mammalian nuclear factor (NF)-
 
k
 
B
 
1
 
 transcription
factors, NF-
 
k
 
B1 (p50/p105), NF-
 
k
 
B2 (p52/p100),
RelA (p65), c-Rel, and RelB are involved in the regula-
tion of immune and inflammatory responses, cellular prolif-
eration, and cell death (for review see references 1–4). NF-
 
k
 
B proteins modulate these diverse biological processes by
regulating the expression of a wide variety of genes encod-
ing cytokines and cytokine receptors, chemokines, cell
adhesion molecules, cell-surface receptors, hematopoietic
growth factors, acute phase proteins, and other transcrip-
tion factors. Transcriptional activation or repression of NF-
 
k
 
B target genes requires binding of NF-
 
k
 
B dimers to 
 
k
 
B
DNA binding sites. Although p50/p65 heterodimers are
considered the prototypical NF-
 
k
 
B dimer, many different
combinations of NF-
 
k
 
B homo- and heterodimers exist (5)
and there is evidence to suggest that these different NF-
 
k
 
B
dimers regulate the expression of different genes (6).
In most cells, the transcriptional activity of NF-
 
k
 
B pro-
teins is controlled at the posttranslational level by regulated
associations with members of the inhibitor (I)
 
k
 
B family of
inhibitory proteins. NF-
 
k
 
B proteins are retained in the cy-
toplasm of unstimulated cells and thus rendered inactive via
interactions with one or more of the seven known I
 
k
 
B
proteins: I
 
k
 
B-
 
a
 
, I
 
k
 
B-
 
b
 
, I
 
k
 
B-
 
g
 
, Bcl-3, I
 
k
 
B-
 
e
 
, p105, and
p100 (3, 7). In response to a wide variety of stimuli, includ-
ing antigen receptor cross-linking, and exposure to cyto-
kines (TNF-
 
a
 
, IL-1), bacterial components (LPS), viruses,
ionizing radiation, or oxidative stress, I
 
k
 
B-
 
a
 
 and -
 
b
 
 pro-
teins are phosphorylated and degraded and cytoplasmic
NF-
 
k
 
B dimers released from their inhibitory proteins are
rapidly translocated to the nucleus where they regulate the
transcription of genes containing 
 
k
 
B binding sites (8–11).
Recent studies have demonstrated that phosphorylation of
Ser
 
32
 
 and Ser
 
36
 
 and subsequent polyubiquitination of I
 
k
 
B-
 
a
 
1
 
Abbreviations used in this paper:
 
 EMSA, electrophoretic mobility shift as-
say; FTOC, fetal thymic organ culture; HA, hemagglutinin; I
 
k
 
B-
 
a
 
, in-
hibitor 
 
k
 
B-
 
a
 
; mI
 
k
 
B-
 
a
 
, mutant I
 
k
 
B-
 
a
 
; NF-
 
k
 
B, nuclear factor 
 
k
 
B;
TUNEL, Tdt-mediated dUTP nick end labeling. 
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are essential for the release and nuclear translocation of NF-
 
k
 
B dimers (12–18). Substitution of I
 
k
 
B-
 
a
 
 Ser
 
32
 
 and Ser
 
36
 
by Ala residues prevents phosphorylation and degradation
of I
 
k
 
B-
 
a
 
, thereby retaining NF-
 
k
 
B dimers in an inactive
form in the cytoplasm.
NF-
 
k
 
B proteins are thought to play important roles in T
cell activation and development (19, 20). Functionally im-
portant 
 
k
 
B binding sites have been identified in a large
number of T cell transcriptional regulatory elements, in-
cluding the IL-2, IL-2R
 
a
 
, G-CSF, and macrophage in-
flammatory protein (MIP)-2 promoters (1). Preformed
NF-
 
k
 
B proteins are present in the cytoplasm of thymocytes
and resting peripheral T cells (21). TCR engagement re-
sults in the rapid phosphorylation of I
 
k
 
B-
 
a
 
 and the con-
comitant nuclear migration of active NF-
 
k
 
B dimers (19,
22, 23). Despite these findings, it has been difficult to pre-
cisely elucidate the role of NF-
 
k
 
B in regulating T cell de-
velopment, activation, and apoptosis in vivo. During the
last several years, gene targeting experiments have demon-
strated that RelB, c-Rel, and NF-
 
k
 
B1 each play important
but distinct roles in regulating the development and func-
tion of the mammalian immune system. NF-
 
k
 
B1–deficient
mice displayed defects in B cell proliferation in response to
the mitogen LPS but not to IgM cross-linking (24, 25).
RelB is required for the differentiation and/or survival of
dendritic cells and thymic medullary epithelial cells and
RelB
 
2/2
 
 mice displayed severely defective cellular im-
mune responses (26, 27). The immune dysfunction ob-
served in RelB
 
2/2
 
 mice was worsened in NF-
 
k
 
B1/RelB
double knockout mice, suggesting that the lack of RelB is
compensated for by other NF-
 
k
 
B1–containing dimers (28).
c-Rel–deficient mice displayed defective B and T cell pro-
liferation in response to mitogen stimulation as well as
markedly decreased IL-2 production after TCR engage-
ment (29). In contrast, mice lacking RelA died on embry-
onic day 15 from massive hepatocyte apoptosis (30, 31).
However, progenitor cells derived from RelA
 
2/2
 
 mice
were able to give rise to normal T cells, suggesting that
RelA is not required for T cell development (30, 32).
Recent studies have suggested that, in addition to regu-
lating lymphocyte function, NF-
 
k
 
B proteins might play a
critical role in protecting cells against apoptosis. Support for
this model came both from the finding of hepatocyte apop-
tosis in the RelA
 
2/2
 
 mice and from experiments demon-
strating that overexpression of a dominant-negative form of
the I
 
kB-a protein in transgenic mice (33) and several cell
lines promoted apoptosis in vitro (34–39). However, other
studies have suggested that NF-kB can also function in a
proapoptotic fashion. For example, induction of apoptosis
in 293 cells after serum withdrawal requires RelA activa-
tion (40). Similarly, radiation-induced apoptosis in ataxia
telangiectasia cells is suppressed by dominant-negative
IkB-a proteins (41) and inhibition of NF-kB activation
prevents apoptosis in cultured human thymocytes (42). Fi-
nally, NF-kB activation promotes apoptosis in neural cells
(43) and T cell hybridomas (44), and high levels of c-Rel
induce apoptosis in avian embryos and in bone marrow
cells in vitro (45).
Although gene targeting experiments have been useful
for identifying the essential nonredundant roles of individ-
ual NF-kB transcription factors in T cell development and
function, the interpretation of these experiments can be
obscured by functional redundancies of related gene prod-
ucts in the mutant animals and by embryonic lethal pheno-
types that preclude a complete analysis of lymphoid devel-
opment and function. Moreover, in some cases it can be
difficult to distinguish cell autonomous and non–cell au-
tonomous phenotypes because mutant animals lack expres-
sion of the targeted gene in all cell lineages. We and others
(33, 46) have used a complementary approach that circum-
vents these potential problems to study the role of NF-kB
in T cell development, activation, and apoptosis in vivo.
Specifically, we have generated transgenic mice that express
a mutant superinhibitory form of the IkB-a protein under
the control of the T cell–specific CD2 promoter and en-
hancer. This superinhibitory form of IkB-a cannot be
phosphorylated on Ser32 and Ser36 and degraded in response
to TCR cross-linking and would therefore be expected to
constitutively inhibit the nuclear translocation of NF-kB
proteins after T cell activation. Studies of the mIkB-a mice
revealed several important functions for NF-kB in T cells
in vivo. First, NF-kB is required to develop or maintain
normal numbers of peripheral CD81 T cells. Second,
NF-kB activation is necessary for both cytokine produc-
tion and thymocyte proliferation after TCR engagement.
Finally and somewhat unexpectedly, NF-kB is required for
a-CD3–mediated apoptosis of double positive (DP) thy-
mocytes in vivo via a pathway that involves downregulated
expression of the antiapoptotic gene bcl-xL in DP thy-
mocytes.
Materials and Methods
Transgene Construction and Generation of Transgenic Mice. The
construction of the hemagglutinin (HA)-tagged IkB-a cDNA
with Ser to Ala substitutions at positions 32 and 36 has been de-
scribed previously (47). The mutant IkB-a cDNA was inserted
into the XhoI site of pTEx (provided by Dr. M. Owen, Imperial
Cancer Research Fund, London, UK), which contains the pro-
moter, polyadenylation site, and locus control region elements
from the human CD2 gene (48). Transgene DNA was microin-
jected into the male pronucleus of fertilized single cell embryos of
CD1 mice. Microinjected eggs were transferred to pseudopregnant
CD1 foster mothers. EcoRI-digested tail DNA from 12–14-d-old
pups was hybridized to a radiolabeled 0.8-kb IkB-a–specific
probe, and the transgene copy number was determined using a
PhosphorImager (Molecular Dynamics).
Cell Culture. Single cell suspensions of thymocytes and sple-
nocytes were cultured at 378C, 5% CO2 in RPMI 1640 medium
containing 10% heat inactivated FCS, 100 U/ml penicillin/strep-
tomycin, 2 mM glutamine, 0.1 mM nonessential amino acids, 5.5 3
102 mM b-ME (all from GIBCO BRL). Thymocyte proliferation
assays were performed in 96-well plates (Becton Dickinson) that
had been coated overnight with a-CD3 mAb (145-2C11;
PharMingen) and/or a-CD28 mAb (37.51; PharMingen) at a
concentration of 16 mg/ml. Stimulation with PMA (Sigma
Chemical Co.) and ionomycin (Calbiochem) was performed at 5
ng/ml and 0.25 mg/ml, respectively. After stimulation for 48 h,147 Hettmann et al.
cells (0.5 3 106/ml) were pulsed for 18 h at 378C with [3H]thy-
midine (1 mCi/ml; Amersham). Cells were transferred onto glass
fiber filter mats and radioactive incorporation was measured with
a beta scintillation counter.
Fetal Thymic Organ Culture. Fetuses of CD1 and mIkB-a
mice were obtained at embryonic day 17.5 of pregnancy, count-
ing the day of vaginal plug as embryonic day 1. Equally sized thy-
mic lobes were cultured in 24-well Transwell dishes (Costar
Corp.) containing complete DMEM-10 medium. The samples
were maintained in an atmosphere of 5% CO2 for 72 h and
treated with a-CD3 mAb (145-2C11) as described in the text.
ELISA Assays. For ELISA assays, 96-well plates (Dynatech
Labs.) were coated overnight at 48C with a–IL-2 (JES6-1A12),
a–IL-3 (MP2-8F8), or a–GM-CSF (MP1-22E9) mAbs (Phar-
Mingen). Serial dilutions of supernatants from thymocytes stimu-
lated in culture for 48 h were added to the antibody-coated plates
and incubated for 18 h at 48C. Biotinylated antibodies against
IL-2 (JES5-5H4), IL-3 (MP2-43D11), or GM-CSF (MP1-31G6)
were then added to the plates and incubated for 2 h at room tem-
perature. Avidin peroxidase (Sigma Chemical Co.) and ABTS (3-
ethylbenzthiazoline-6-sulfonic acid) were added to the wells and
enzymatic reactions were quantitated in a microplate reader (Dy-
natech Labs.). All samples were assayed in triplicate.
Western Blot Analysis. Cytoplasmic and nuclear thymocyte
extracts were prepared as previously described (49). In brief, thy-
mocytes were washed with PBS, incubated in buffer A (10 mM
Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithio-
threitol, and 0.2 mM phenylmethylsulfonyl fluoride) for 10 min
at 48C and centrifuged to separate nuclei (pellet) from cytoplas-
mic proteins (supernatant). Nuclei were lysed by incubation with
buffer C (20 mM Hepes, pH 7.9, 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM
phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, and 10 mg/ml
leupeptin) at 48C and lysates were cleared by centrifugation. Nu-
clear and cytoplasmic extracts were frozen at 2708C. Protein
concentrations were determined using a commercially available
kit (Bio-Rad). For Western blot analysis, 15 mg of cytoplasmic
extracts were fractionated by SDS-PAGE in 10% polyacrylamide
gels and transferred to PVDF membranes (Millipore). Western
blots were probed with a rabbit polyclonal antibody against
MAD-3 (1:2,000 dilution; nomenclature of DiDonato et al. [ref-
erence 13], No. 644) or an a-HA-specific antibody (1:2,000
dilution; 12CA5). Blots were developed with goat a-rabbit
(1:2,000 dilution; Amersham) or rat a-mouse (1:5,000 dilution;
Kirkegaard and Perry Labs.) secondary antibodies and a commer-
cially available chemiluminescence kit according to the manufac-
turer’s instructions (Pierce Chemical Co.).
Electrophoretic Mobility Shift Assay. A double-stranded oligo-
nucleotide, spanning the kB site of the IL-2Ra promoter (50)
(59 GGAACGGCAGGGGAATTCCCCTCTCCTT 39) was la-
beled with 32P-nucleotides using the Klenow fragment of DNA
polymerase I. Binding reactions contained 2 mg nuclear extract,
20,000 disintegrations per min (0.1–0.5 ng) of radiolabeled oligo-
nucleotide probe, 2 mg poly (dI-dC) in 75 mM KCl, 10 mM
Tris, pH 7.5, 1 mM dithiothreitol, 1 mM EDTA, and 4% (vol/
vol) Ficoll in a final volume of 20 ml. After incubation on ice for
30 min, DNA protein complexes were fractionated by electro-
phoresis in nondenaturing 4% polyacrylamide gels at 120 V for
2.5 h in running buffer (25 mM Tris, 25 mM Boric acid, and 0.5
mM EDTA) with 47 mM b-ME. For competition experiments,
50 ng of unlabeled NF-kB oligonucleotide was added to the
binding reaction before addition of the radiolabeled oligonucle-
otide probe. For antibody supershift experiments, the nuclear ex-
tracts were incubated with 1 ml of a-p50 (F056), a-RelB (A277),
a-p65 (B127), or a-c-Rel (L036) antibodies (all from Santa Cruz
Biotechnology) before starting the binding reactions.
Flow Cytometry. Single cell suspensions of lymphocytes (106
cells) were washed in PBS and incubated with PE–a-CD4
(RM4-5), FITC–a-CD8 (53-6.7), FITC–a-CD3 (145-2C11),
and/or PE–a-TCR-a/b (H57-97) mAbs (PharMingen) in PBS
plus 0.1% BSA for 30 min on ice. After staining, the cells were
washed in PBS and analyzed on a FACScan® (Becton Dickinson).
Each plot represents analysis of .104 events using WinMDI soft-
ware (Windows Multiple Document Interface, version 2.5). For in-
tracellular staining, 106 thymocytes were stained with Cy-Chrome–
a-CD4 (RM4-5) and PE–a-CD8 (53-6.7), and fixed in 4%
paraformaldehyde. Fixed thymocytes were washed with 0.03%
saponin (Sigma Chemical Co.) and incubated with 100 ml 0.3%
saponin, 20 ml blocking serum (Sigma Chemical Co.) and FITC–
a-Bcl-xL (7B2.5) (Southern Biotechnology Associates). After 30
min of incubation at 48C, cells were washed twice in 0.03% saponin
followed by one wash in FACS buffer before FACScan® analysis.
Ribonuclease Protection Assays. Ribonuclease protection assays
were performed using a commercially available kit as described
by the manufacturer (PharMingen) using the mAPO-2 multi-
probe template set, 10 mg thymic RNA, and 0.1 mCi a-[32P]UTP
(Amersham). RNAse–protected fragments were resolved by elec-
trophoresis in polyacrylamide gels and visualized by autoradiogra-
phy (Eastman Kodak Co.).
TUNEL Assays. TUNEL (Tdt-mediated dUTP nick end la-
beling) assays were performed on paraffin-embedded sections of
thymi according to Gavrieli et al. (51). Photomicrographs were
obtained with a Zeiss Axioskop.
Results
Production of mIkB-a Transgenic Mice. To inhibit induc-
ible NF-kB activity in thymocytes in vivo, we produced
transgenic mice that expressed a “superinhibitory” form of
IkB-a under the control of the T cell–specific CD2 pro-
moter and enhancer (mIkB-a mice). We chose to use an
IkB-a transgene because previous studies have demon-
strated that IkB-a plays a critical role in regulating induc-
ible NF-kB expression (for review see references 2–4,
52).  The superinhibitory mIkB-aA32/36 transgene containing
Ser32 and Ser36 to Ala substitutions cannot be phosphory-
lated and degraded in response to TCR engagement and
would therefore be expected to constituitively inhibit NF-
kB activity in both resting and activated thymocytes and T
cells. The CD2 promoter and enhancer (48, 53; Fig. 1 A)
were used in these studies because (a) they program T cell–
specific transgene expression and (b) they are expressed at
high levels in all thymocyte subsets including double nega-
tive (CD42CD82; DN), DP (CD41CD81), and single
positive (CD41 or CD81; SP) cells (54). The transgene
construct also contained three copies of an 11-amino acid
influenza virus HA epitope tag (55) that allowed us to dis-
tinguish the transgene-encoded protein from endogenous
murine IkB-a. A line of mIkB-a mice containing z12
copies of the transgene was produced by injection of this
construct into fertilized CD1 mouse embryos (Fig. 1 B).
Homozygous transgenic mice were generated by breeding
heterozygous littermates in order to obtain maximal levels148 NF-kB and Thymocyte Apoptosis
of IkB-aA32/36 protein expression, an important consider-
ation in producing a dominant-negative phenotype. A sec-
ond line of transgenic mice expressing the IkB-aA32/36
cDNA under the control of the proximal lck promoter and
the CD2 enhancer was also produced (data not shown).
Similar phenotypes were observed in both lines of trans-
genic mice and are therefore not distinguished in the results
described below.
Endogenous IkB-a is phosphorylated and degraded after
treatment of T cells with the NF-kB inducer, TNF-a (47).
To analyze the relative levels of endogenous and transgene-
encoded IkB-a and to study the differential regulation of
the two proteins in response to TNF-a, we performed
Western blot analyses using whole cell extracts from mIkB-a
and control thymocytes that had been treated for different
times with TNF-a (Fig. 2 A). Basal levels of the IkB-aA32/36
protein as detected with both the a-HA and a-IkB-a
(a-MAD) antibodies slightly exceeded levels of the endog-
enous IkB-a protein in the mIkB-a thymocytes. In both
wild-type and mIkB-a thymocytes, endogenous IkB-a
was almost completely degraded after 15 min of TNF-a
treatment and remained undetectable until z30 min after
treatment. As previously reported (9, 15), endogenous
IkB-a was reexpressed between 30 and 60 min after TNF-a
treatment (data not shown). This reexpression reflects NF-
kB–mediated activation of the IkB-a promoter. In marked
contrast, levels of the transgene-encoded IkB-aA32/36 were
unchanged by TNF-a treatment at all time points (Fig. 2
A). Activation of mIkB-a thymocytes with PMA plus ion-
omycin or TCR cross-linking resulted in a similar degrada-
tion of endogenous IkB-a, whereas the levels of IkB-aA32/36
remain unaffected (data not shown).
To analyze the effects of IkB-aA32/36 expression on the
nuclear translocation of NF-kB proteins after T cell activa-
tion, we performed electrophoretic mobility shift assays
(EMSAs) using nuclear extracts prepared from both resting
thymocytes and thymocytes activated in vivo by intraperi-
toneal injection of an a-CD3 mAb (Fig. 2 B). As reported
previously, nuclear extracts from unstimulated wild-type
and mIkB-a thymocytes both contained p50 homodimers
that bound to the radiolabeled kB probe (22, 56). The
presence of such p50 homodimers in uninduced thymic
nuclear extracts probably reflected the fact that p50 binds to
IkB proteins with lower affinity and therefore is not quan-
titatively retained in the cytoplasm of either wild-type or
mIkB-a thymocytes (57). Because p50 homodimers do
not contain a transcriptional activation domain they are
thought to repress kB-dependent gene expression (58).
After activation with a-CD3 mAb, the level of p50
homodimers increased equivalently in the wild-type and
mIkB-a thymocyte nuclear extracts. In addition, an induc-
ible low mobility kB binding complex appeared in the
nuclear extracts of wild-type thymocytes. Antibody super-
shift experiments demonstrated that this complex contained
predominantly p50/p65 heterodimers as well as smaller
amounts of c-Rel– and RelB-containing heterodimers
(Fig. 2 B). The induction of this low mobility kB binding
activity was markedly inhibited after a-CD3–mediated ac-
tivation of the mIkB-a thymocytes (Fig. 2 B). Taken to-
gether, these Western blotting and EMSA experiments
demonstrated that thymocytes from the mIkB-a transgenic
animals expressed high levels of cytoplasmic IkB-aA32/36
protein that was not degraded after TCR engagement in
vivo. Moreover, constitutive expression of the IkB-aA32/36
protein significantly reduced the induction of nuclear p50/
p65, c-Rel/p50, and RelB/p50 NF-kB heterodimers af-
ter either TNF-a or a-CD3–mediated activation of the
mIkB-a thymocytes.
Normal Thymocyte Ontogeny in the mIkB-a Transgenic
Mice. To investigate T cell development in the mIkB-a
mice, thymocytes and peripheral T cells from transgenic
and wild-type animals were analyzed by flow cytometry
using antibodies specific for a variety of developmentally
regulated T cell surface antigens (Fig. 3). Thymi from the
mIkB-a animals contained normal populations of DN, DP,
and SP cells. Levels of CD3 and TCR-a/b expression were
also indistinguishable on wild-type and mIkB-a thymo-
cytes (Fig. 3 B), as were expression of TCR-g/d and
heat-shock antigen (data not shown). Thus, expression of
IkB-aA32/36 did not appear to perturb thymocyte ontogeny.
Total numbers of SP peripheral T cells in both the spleen
and the lymph nodes were normal in mIkB-a mice as were
Figure 1. Production of
mIkB-a transgenic mice. (A)
Schematic illustration of the
IkB-aA32/36 transgene. Nucle-
otide and amino acid sequences
corresponding to amino acids 31
to 37 from the wild-type human
IkB-a cDNA (94) and the mu-
tant IkB-aA32/36 are shown
above the schematic representa-
tion of the transgene construct.
Site-specific mutations within
the IkB-aA32/36 cDNA sequence
are underlined and the resulting
Ser to Ala substitutions are circled. The HA epitope (HA), CD2 promoter (CD2-Pr), polyadenylation signal (poly A), and the CD2 enhancer/LCR
(CD2 Enh) are also shown. (B) Southern blot analysis of tail DNA from wild-type (WT) and mIkB-a transgenic (Tg) mice was performed with a radio-
labeled 0.8-kb IkB-a cDNA probe (see A) that hybridizes to both the transgene (IkB-aA32/36) and the endogenous IkB-a gene. Size markers in kilobases
are shown to the right of the autoradiogram.149 Hettmann et al.
the numbers of splenic CD41 T cells. However, as de-
scribed previously by Boothby at al. and Esslinger et al. (33,
46), the numbers of peripheral CD81 T cells were reduced
by z50% in mIkB-a mice (Fig. 3 C).
Impaired Proliferation and Cytokine Production by mIkB-a
Transgenic Thymocytes. To assess the effects of IkB-aA32/36
expression on cytokine production and proliferation, thymo-
cytes from mIkB-a and wild-type control littermates were ac-
tivated in vitro for 72 h with PMA plus ionomycin, a-CD3
mAb, or a-CD3 plus a-CD28 mAbs. When compared with
wild-type thymocytes, proliferation of the mIkB-a thymo-
cytes was reduced by 63% in response to PMA plus ionomy-
cin and by 78% after activation with a-CD3 mAb (Fig. 4).
Previous studies have suggested that CD28 costimulation may
function, at least in part, through an NF-kB–dependent path-
way (59). Therefore, we tested the ability of CD28 costimula-
tion to rescue the defect in a-CD3–mediated thymocyte pro-
liferation seen in the mIkB-a thymocytes. Interestingly, the
observed reductions in thymocyte proliferation were partially,
but not completely, rescued by a-CD28 costimulation (Fig.
4). Thus, the CD28 signaling pathway can at least partially
bypass the requirement for NF-kB activation in thymocyte
activation by TCR engagement.
Many cytokine genes including IL-2, IL-3, and GM-
CSF are potential targets for NF-kB (60). However, the
role of NF-kB in regulating activation-specific cytokine
expression in vivo, particularly the expression of the IL-2
gene, remains controversial. Therefore, we compared cy-
tokine production by the wild-type and mIkB-a thy-
mocytes after activation with a-CD3 plus a-CD28 mAbs
(Fig. 5). As compared with wild-type thymocytes, the
mIkB-a thymocytes displayed significantly decreased pro-
duction of IL-2, IL-3, and GM-CSF after a-CD3 plus
a-CD28 activation (Fig. 5). IL-2 production was most
significantly reduced (28% of wild-type levels), whereas
GM-CSF and IL-3 production were less dramatically in-
hibited (Fig. 5). Taken together, these experiments demon-
Figure 2. IkB-a and NF-kB expression in the mIkB-a transgenic
mice. (A) Western blot analysis of IkB-a expression in thymocytes from
mIkB-a transgenic mice after treatment with TNF-a. Thymocytes from
wild-type (WT) and mIkB-a transgenic (Tg) mice were incubated with
TNF-a (15 ng/ml) for the indicated times and cytoplasmic extracts were
separated by electrophoresis in a denaturing polyacrylamide gel. Proteins
were transferred to a PDVF membrane and immunoblotted with either a
murine HA-specific antibody (a-HA) or a rabbit polyclonal antibody spe-
cific for IkB-a (a-MAD) (13). The positions of the endogenous IkB-a
and IkB-aA32/36 transgene-encoded proteins are shown to the left of the
autoradiogram. Size markers in kilodaltons are shown to the right of the
autoradiogram. (B) EMSA of NF-kB expression in transgenic thymocytes
after stimulation in vivo with a-CD3 mAb. Thymic nuclear extracts (2 mg)
from mice treated for 3 h with a single intraperitoneal injection of a-CD3
mAb or PBS (control) were analyzed by EMSA with a radiolabeled kB
oligonucleotide probe. For antibody supershift experiments, thymic nu-
clear extracts were preincubated with antibodies specific for NF-kB p50,
p65, c-Rel, or RelB. For cold competition experiments, binding reac-
tions contained a 50-fold molar excess of unlabeled competitor oligonu-
cleotide. The positions of bands corresponding to binding of NF-kB p50
homodimers and p65/p50 as well as c-Rel/p50 and RelB/p50 het-
erodimers are indicated, as are “supershifted” complexes containing p50,
p65, c-Rel, and RelB proteins (d).
Figure 3. T cell development in mIkB-a transgenic mice. Single cell suspensions of thymocytes from mIkB-a transgenic (Tg) and wild-type (WT) mice
were stained with PE–a-CD4 and FITC–a-CD8 (A), or PE–a-TCR-a/b and FITC–a-CD3 (B) antibodies and analyzed by flow cytometry. Percentages of
cells in the individual subpopulations are shown in the lower right quadrant. (C) Splenocytes from mIkB-a transgenic (Tg) and wild-type (WT) mice were
stained with 7-amino actinomycin D, PE–a-CD4, and FITC–a-CD8, and were analyzed by flow cytometry. Total numbers (3 106 cells) of live CD41 and
CD81 splenic T cells were determined from at least three mice in each group. The data is shown as mean 6 SD.
Figure 4. Defective prolifera-
tion of mIkB-a thymocytes in
response to mitogenic stimuli.
Wild-type (WT) and mIkB-a
transgenic (Tg) thymocytes were
incubated with PMA (5 ng/ml)
plus ionomycin (0.25 mg/ml; P 1
I), or stimulated with immobilized
a-CD3 or a-CD3 plus a-CD28
antibodies (16 mg/ml) for 60 h at
378C. Proliferation was measured
by [3H]thymidine incorporation.150 NF-kB and Thymocyte Apoptosis
strated that NF-kB is required both for the induction of
multiple cytokines and for normal thymocyte proliferation
after TCR cross-linking.
DP IkB-aA32/36 Thymocytes Are Protected against a-CD3–
mediated Apoptosis In Vivo. Systemic administration of a-CD3
mAb has been shown to result in the rapid depletion of
.90% of DP thymocytes by apoptosis (61). NF-kB posi-
tively regulates the expression of death-rescuing genes,
thereby preventing TNF-a–induced apoptosis at least in cer-
tain cell types (34–39). Based upon these findings, it was rea-
sonable to hypothesize that DP thymocytes from the mIkB-a
mice that failed to activate NF-kB normally would display
increased apoptosis after systemic administration of a-CD3
mAb. To directly test the role of NF-kB in mediating
the a-CD3–mediated apoptotic death of DP thymocytes,
mIkB-a and wild-type animals were injected intraperito-
neally with a-CD3 mAb and thymocyte subsets were as-
sessed by flow cytometry 48 h after injection. As shown in
Fig. 6 and consistent with previous reports (62, 63), treat-
ment of wild-type animals with a-CD3 mAb resulted in
dose-dependent reductions in the size of the DP thymocyte
population. Wild-type animals treated with 40 mg of a-CD3
mAb displayed a 98% reduction in DP thymocytes within
48 h after a-CD3 administration. Somewhat surprisingly, this
a-CD3–mediated loss of DP thymocytes was completely
and reproducibly prevented in the mIkB-a mice even after
administration of 40 mg of a-CD3 mAb (Fig. 6). Similar re-
ductions in DP thymocyte apoptosis were observed at both
24 and 48 h after injection and after administration of either
20 or 40 mg of a-CD3 mAb (Fig. 6 and data not shown).
To confirm the protective effects of IkB-aA32/36 expres-
sion on DP thymocyte apoptosis in vivo, we performed
TUNEL assays on thymi from wild-type and mIkB-a mice
after intraperitoneal injection of a-CD3 mAb (Fig. 7).
Large numbers of apoptotic cells were seen in wild-type
thymi after treatment with a-CD3 mAb as compared with
littermates treated with an isotype-matched control anti-
body. In contrast, the frequency of apoptotic cells in the
mIkB-a thymi was dramatically reduced as compared with
that observed in wild-type thymi after treatment with simi-
lar amounts of a-CD3 mAb (Fig. 7).
Figure 5. Reduced cytokine
production by mIkB-a trans-
genic thymocytes. Cultured thy-
mocytes from wild-type (white
bars) and transgenic IkB-aA32/36
mice (black bars) were stimulated
with immobilized a-CD3 plus
a-CD28 antibodies (16 mg/ml).
The levels of IL-2, GM-CSF,
and IL-3 in the culture super-
natants were assayed by ELISA
48 h after stimulation.
Figure 6. Decreased a-CD3–mediated deletion of DP thymocytes in mIkB-a transgenic mice. (A) 3–7-wk-old wild-type (WT) or mIkB-a trans-
genic mice (Tg) were injected intraperitoneally with 200 ml of PBS containing either 0 (Control), 20, or 40 mg of a-CD3 mAb. Freshly isolated thy-
mocytes from these animals were analyzed by flow cytometry with PE–a-CD4 and FITC–a-CD8 48 h after a-CD3 administration. (B) Absolute num-
bers of thymocytes in wild-type (n 5 3) and mIkB-a transgenic (n 5 4) animals 48 h after intraperitoneal injection with PBS or 40 mg of a-CD3 mAb.
The data are shown as mean 6 SEM. (C) 3–7-wk-old wild-type (WT) or mIkB-a transgenic mice (Tg) were treated with whole body g irradiation (500
RADs). Freshly isolated thymocytes from these animals were analyzed by flow cytometry with PE–a-CD4 and FITC–a-CD8 12 h after g irradiation.151 Hettmann et al.
DP IkB-aA32/36 Thymocytes Remain Sensitive to g Irradia-
tion–induced Apoptosis In Vivo. Like a-CD3 treatment, g
irradiation of the thymus is known to cause DP thymocyte
apoptosis in vivo (64). However, recent studies have sug-
gested that these different apoptotic stimuli may use distinct
signaling pathways to regulate programmed cell death.
Given the resistance of mIkB-a DP thymocytes to
a-CD3–mediated apoptosis, it was of interest to determine
the sensitivity of these cells to g irradiation in vivo. As
shown in Fig. 6 C, DP thymocytes from the mIkB-a mice
remained fully sensitive to g irradiation–induced apoptosis
in vivo. Thus, expression of the IkB-aA32/36 transgene pro-
tected DP thymocytes from apoptosis in response to a-CD3
but failed to protect these cells against g irradiation–
induced cell death.
DP mIkB-a Thymocytes Are Resistant to a-CD3–mediated
Apoptosis in Fetal Thymic Organ Culture. The administration
of  a-CD3 mAbs to mice in vivo can effect thymocytes either
directly or indirectly via the activation of peripheral blood
CD31 T cells. To attempt to distinguish these possibilities, we
tested the susceptibility of mIkB-a thymocytes to a-CD3–
mediated apoptosis in fetal thymic organ culture (FTOC)
(Fig. 8). Wild-type thymocytes were killed efficiently by 3 d
of FTOC treatment with an a-CD3 mAb. In contrast, DP
thymocytes from the mIkB-a mice were relatively resistant
to a-CD3–mediated killing in FTOC. These results suggested
that at least some of the resistance to a-CD3–mediated DP
thymocyte apoptosis seen in the mIkB-a mice reflects a
thymus-specific effect of transgene expression.
DP mIkB-a Thymocytes Fail To Downregulate Bcl-xL after
a-CD3 Treatment In Vivo The Bcl-2 family of proteins is
comprised of multiple members that function either as
death agonists (Bax, Bak, Bcl-XS, and Bad) or death antag-
onists (Bcl-2, Bcl-xL, Bcl-xg, Mcl-1, A1, and Bcl-w) (65).
Two antiapoptotic members of this family, Bcl-xL and Bcl-2,
are expressed in a reciprocal pattern during thymocyte de-
velopment. Bcl-2 is expressed at high levels in immature
DN thymocytes. Its expression is downregulated in DP
cells and it is then reexpressed as these DP cells mature to
SP thymocytes and peripheral T cells (66, 67). Conversely,
Bcl-xL is expressed at low or undetectable levels in imma-
ture DN cells. Its expression is significantly upregulated in
DP thymocytes, and it is then downregulated as these cells
progress to the SP stage of thymocyte ontogeny (68, 69).
Interestingly, DP thymocytes from transgenic mice that
overexpress Bcl-2 or Bcl-xL are protected from multiple
proapoptotic stimuli, including a-CD3 treatment in vivo
(69, 70). Given these findings, it was logical to postulate
that altered expression of Bcl-2-family genes in the mIkB-a
thymocytes might account for their decreased susceptibility
to proapoptotic stimuli. Accordingly, we used an RNAse
protection assay to directly monitor the expression of Bcl-
2–related genes in thymocytes from wild-type and mIkB-a
transgenic mice. As shown in Fig. 9 A, both basal and
a-CD3–treated levels of bfl-1, bak, bax, bcl-2, and bad
mRNAs were equivalent in wild-type and mIkB-a thymo-
cytes. Similarly, we failed to detect differential expression
of mRNAs encoding Fas, Fas-L, TRAF, TRADD, Fadd,
RIP, and FLICE in either unstimulated or a-CD3–treated
wild-type and mIkB-a thymocytes (data not shown). Basal
levels of bcl-xL were equivalent in wild-type and mIkB-a
thymocytes. However, after a-CD3 treatment, the expres-
sion of bcl-xL was significantly decreased in the wild-type
cells but was maintained at pretreatment levels in the
mIkB-a thymocytes (Fig. 9 A).
Because Bcl-xL is the predominant antiapoptotic protein
expressed in DP thymocytes, the preferential loss of Bcl-xL
Figure 7. Decreased a-CD3–mediated thymocyte apoptosis in mIkB-a
transgenic mice. Wild-type (WT) or mIkB-a transgenic (Tg) mice were
injected intraperitoneally with 40 mg of a-CD3 mAb or an isotype-
matched control antibody. Thymi were harvested and sections were ana-
lyzed for apoptotic lymphocytes by TUNEL assay. Each photomicro-
graph is representative of at least four different sections taken from each
thymus. Original magnification: 3400. Figure 8. Decreased a-CD3–mediated deletion of DP thymocytes in
FTOCs from mIkB-a transgenic mice. Thymi from embryonic day 17.5
wild-type (WT) or mIkB-a transgenic (Tg) mice were cultured for 72 h
on semipermeable membranes in DMEM-10 plus 10% FCS in the ab-
sence (untreated) or presence of 10 mg/ml a-CD3 mAb (a-CD3). Thy-
mocytes were analyzed by flow cytometry with PE–a-CD4 and FITC–
a-CD8. Percentages of cells in the individual subpopulations are shown
in the lower left quadrant.152 NF-kB and Thymocyte Apoptosis
from wild-type thymocytes after a-CD3 administration
might have simply reflected the death of these DP cells. To
confirm that the pattern of Bcl-xL protein expression paral-
leled that of the mRNA and to assess the possibility that the
observed changes in bcl-xL mRNA expression reflected the
preferential death of the DP thymocytes in the wild-type
animals, we performed Western blot analyses on thymocyte
extracts 18 and 39 h after a-CD3 treatment in vivo. As
shown in Fig. 9 B, levels of Bcl-xL protein were signifi-
cantly reduced in wild-type thymocytes at both 18 and
39 h after administration of a-CD3 mAb. In contrast, levels
of Bcl-xL protein were maintained at unstimulated levels in
the mIkB-a thymocytes at both time points. Because there
is not a significant loss of DP thymocytes 18 h after a-CD3
treatment, these results indicated that the loss of Bcl-xL
protein precedes thymocyte apoptosis and is prevented in
the mIkB-a DP thymocytes. We confirmed this result by
performing intracellular staining of viable DP thymocytes
using Bcl-xL–specific antibodies (Fig. 9 C). 24 h after
a-CD3 administration, viable DP thymocytes displayed a
significant decrease in intracellular Bcl-xL as measured by
flow cytometry. In contrast, DP thymocytes from the
mIkB-a mice failed to downregulate intracellular Bcl-xL
expression. In control experiments, SP CD41 thymocytes
from these same wild-type and mIkB-a animals both failed
to demonstrate altered levels of intracellular Bcl-xL after
a-CD3 administration (Fig. 9 D). Taken together, these
results demonstrated that the in vivo administration of
a-CD3 mAb resulted in the specific downregulation of the
antiapoptotic gene bcl-xL in DP thymocytes and that this
reduced expression of Bcl-xL was, in turn, associated with
subsequent apoptotic cell death. In contrast, DP thymo-
cytes from mIkB-a mice failed to downregulate Bcl-xL and
were protected from a-CD3–mediated programmed cell
death.
Discussion
In the studies described in this report, we have used
transgenic mice expressing a superinhibitory form of IkB-a
to study the function of NF-kB in T cells in vivo. The
dominant-negative approach used in these studies circum-
vents potential problems of functional redundancy and em-
bryonic lethality that can complicate the analysis of gene
Figure 9. An NF-kB–mediated pathway downregulates the expression of bcl-xL after a-CD3 admin-
istration in vivo. (A) Expression of Bcl-2–related genes in thymocytes after administration of a-CD3
mAb. Wild-type (WT) or mIkB-a transgenic mice (IkB-aA32/36) were injected intraperitoneally with
200 ml of PBS containing 0 (2) or 40 mg of a-CD3 mAb and thymocyte RNA was prepared 24 or 48 h
after treatment. Expression of Bcl-2–related mRNAs was quantitated by RNAse protection assay. L32
is a control RNA that is present at equivalent levels in each of the samples assayed. Note the specific re-
duction in bcl-xL mRNA levels in the WT thymocytes that was prevented in the mIkB-a thymocytes.
(B) Western blot analysis of Bcl-xL expression in wild-type (WT) or mIkB-a (IkB-aA32/36) thymocytes
from mice injected intraperitoneally with 40 mg of a-CD3 mAb for the times shown. Equivalent levels
of expression of a slow mobility nonspecific control band demonstrate equal loading of the gel. (C and D) Expression of Bcl-xL in viable thymocytes from
wild-type (WT) or mIkB-a (IkB-aA32/36) transgenic mice 24 h after intraperitoneal injection with 40 mg of a-CD3 mAb (dotted lines) or an isotype-
matched control antibody (Control Ab; solid lines). Viable thymocytes (as determined by forward and side scatter gating) were analyzed by flow cytom-
etry with Cy-Chrome–a-CD4 and PE–a-CD8 (see inserts for FACS® profiles). Thymocytes were fixed, permeabilized, and stained with an FITC–
a-Bcl-xL mAb. Levels of intracellular Bcl-xL in specific subpopulations of thymocytes were analyzed by gating on DP (C) and CD41 SP cells (D). Note
the reduction in intracellular Bcl-xL levels seen in the wild-type DP thymocytes after a-CD3 treatment, which was observed neither in the mIkB-a DP
thymocytes nor in the wild-type or mIkB-a SP thymocytes from these same animals.153 Hettmann et al.
targeting experiments. In addition, because the transgene is
only expressed in thymocytes and T cells we can conclude
that the observed defects in T cell function are thymocyte
or T cell autonomous. Our results have revealed several
important roles for NF-kB proteins in T cell development
and function. First in agreement with previous reports (33,
46) we showed that NF-kB is required for the develop-
ment and/or survival of normal numbers of peripheral
CD81 T cells, for the inducible expression of multiple cy-
tokine genes, and for normal T cell proliferation in re-
sponse to TCR-mediated T cell activation. However, our
studies have also revealed an unexpected and novel role for
NF-kB proteins in DP thymocyte apoptosis in response to
a-CD3 mAb administration in vivo.
Defective Thymocyte Proliferation and Cytokine Production in
the mIkB-a Mice. TCR engagement leads to the precisely
orchestrated transcriptional induction of .100 new genes
whose expression together determine the activated T
cell phenotype. Several inducible transcription factors
have been implicated as critical early regulators of activa-
tion-specific T cell gene expression. These include NF-AT,
CREB, AP1, and NF-kB (60). Three of these, NF-AT,
CREB, and NF-kB, are present in an inactive form in rest-
ing T cells and are activated by posttranslational phosphor-
ylation or dephosphorylation in response to TCR cross-
linking. The precise role of each of these transcription
factors in regulating T cell activation remains unclear be-
cause many T cell genes contain binding sites for multiple
inducible transcription factors, and because it has been dif-
ficult to extrapolate from the results of transient transfec-
tion assays performed in immortalized T cell lines to in
vivo transcriptional regulatory pathways. Thus, for exam-
ple, NF-AT, AP1, and NF-kB transcription factors can
each bind to functionally important sites in the IL-2 pro-
moter in vitro (71–74). Moreover, transient transfection as-
says have suggested that each of these transcription factors
may play an important role in regulating the expression of
this T cell cytokine (75–76). However, gene targeting ex-
periments have thus far failed to demonstrate a critical role
for NF-AT in positively regulating IL-2 expression and T
cell proliferation in normal T cells (77, 78). To circumvent
these problems, we used a genetic approach involving over-
expression of IkB-aA32/36 in transgenic mice to directly study
the role of NF-kB proteins in the development and activa-
tion of normal T cells in vivo. Our results demonstrated that
NF-kB is required for the inducible expression of the IL-2,
IL-3, and GM-CSF genes and for subsequent T cell prolifer-
ation in response to TCR stimulation. These findings are
consistent with similar defects in cytokine production and T
cell proliferation observed in mice lacking the c-Rel protein
(29) or expressing a constitutively active IkB-a transgenic
protein containing an NH2-terminal deletion (33).
Previous studies have suggested that the CD28 costimu-
latory pathway functions to activate cytokine gene tran-
scription via an NF-kB–mediated signaling pathway (59,
79–81). Interestingly, however, we and others (33) found
that the inhibitory effects of IkB-aA32/36 on a-CD3–medi-
ated thymocyte proliferation could be partially reversed by
a-CD28–mediated costimulation. This suggests that at least
some of the costimulatory effects of the CD28 pathway are
mediated via one or more NF-kB–independent pathways.
In this regard, it is of interest that a-CD28 costimulation
has also been reported to increase IL-2 expression by stabi-
lizing IL-2 mRNA (82). It will be of interest to determine
if this mRNA-stabilizing effect of CD28 signaling is regu-
lated via an NF-kB–independent pathway.
The mechanism responsible for the observed reduction
in peripheral CD81 T cells in the mIkB-a mice remains
unclear. It may reflect unique roles for NF-kB in the sig-
naling pathways required for the maturation or export of
mature CD81 thymocytes. Alternatively, it may reflect a
defect in the survival of CD81 T cells in the periphery of
the mIkB-a mice. In this regard, it is of interest that the
survival of peripheral naive SP CD81 T cells has been re-
ported to require continuous stimulation by class I MHC.
Thus, it is possible that this class I MHC–mediated signal is
transmitted through an NF-kB–dependent pathway (83).
The Role of NF-kB in DP Thymocyte Apoptosis. Pro-
grammed cell death plays an important role in shaping the
T cell repertoire during thymocyte ontogeny. More than
95% of immature DP thymocytes die before they exit the
thymus (84). Thymocytes that express TCRs with low
avidity for antigen plus self-MHC fail to be positively se-
lected and die by “neglect”, whereas self-reactive DP T
cells are deleted during the process of negative selection af-
ter high affinity engagement of their TCRs by self-anti-
genic peptides and MHC (85, 86). Our results demonstrate
that NF-kB proteins are necessary positive mediators of DP
thymocyte apoptosis in response to a-CD3 administration
in vivo. These findings were somewhat surprising given
several recent studies that have reported that NF-kB pro-
teins are potent inhibitors of TNF-a– and IL-1–mediated
apoptosis in fibroblasts (36–39, 87). However, our findings
are consistent with previous reports demonstrating that
NF-kB proteins can positively regulate apoptosis in certain
cell types in vitro including thymocytes and T cell hybrido-
mas (42, 44). The different findings of these studies may re-
flect the fact that NF-kB can regulate the expression of dis-
tinct proapoptotic and antiapoptotic programs in different
cell lineages, at different developmental stages of a single
lineage, and/or in response to different extracellular signals.
At least three different apoptotic pathways have been
identified in thymocytes: (a) a TCR-mediated pathway (63,
88); (b) a glucocorticoid-responsive pathway (89, 90); and
(c) a g irradiation–sensitive pathway (64). Recent evidence
has suggested that these pathways can be distinguished at a
molecular level. Thus, for example, g irradiation–induced
thymocyte apoptosis requires p53 and does not occur in
p53-deficient thymocytes. In contrast, a-CD3–mediated
thymocyte apoptosis is p53 independent (64, 91). Our results
are consistent with such a model in that the mIkB-a DP
thymocytes were protected from a-CD3–induced apoptosis
but remained sensitive to programmed cell death induced by
g irradiation. Thus, we would suggest that NF-kB is not re-
quired for p53-dependent thymocyte apoptosis, but is a crit-
ical positive regulator of at least one p53-independent path-154 NF-kB and Thymocyte Apoptosis
way of programmed cell death in DP thymocytes. In this
regard, it will be of interest to study DP thymocyte apoptosis
in p53-deficient, mIkB-a transgenic mice.
Our results suggest that NF-kB mediates a-CD3–medi-
ated apoptosis in wild-type DP thymoctyes by downregulat-
ing the expression of the antiapoptotic gene bcl-xL. Because
bcl-xL is the predominant antiapoptotic gene expressed in DP
thymocytes (68, 69) it is not surprising that its downregula-
tion would predispose these cells to apoptosis. Such a model
is also consistent with previous studies that have demon-
strated that constitutive expression of a bcl-xL transgene in
DP thymocytes protects them from a-CD3–mediated apop-
tosis (69). Recently, an alternatively spliced form of bcl-xL
called bcl-xg has been shown to be expressed in DP thymo-
cytes and to be regulated in response to TCR stimulation
(92). Because the Bcl-xL and Bcl-xg proteins are virtually
identical in size and are both recognized by the anti-Bcl-xL
antibodies and probes used in our studies, we cannot distin-
guish them by RNAse protection, Western blotting, or in-
tracellular flow cytometry. Thus, it is possible that one or
both isoforms of Bcl-x contribute to the antiapoptotic effects
of the IkB-aA32/36 transgene. The effect of NF-kB on Bcl-xL
expression in DP thymocytes may be direct or indirect. That
is, NF-kB proteins might bind directly to the bcl-xL pro-
moter and downregulate its activity, or alternatively, might
control the expression of other (positive and/or negative)
regulators of the bcl-xL gene in thymocytes. In this regard, it
will be of interest to further characterize the bcl-xL promoter
and to study its regulation by NF-kB proteins.
It is important to emphasize that at present, we cannot
conclude that the proapoptotic effects of NF-kB in DP
thymocytes are thymocyte autonomous. For example, it is
possible that a-CD3 administration causes peripheral T cell
activation resulting in cytokine expression that in a para-
crine fashion causes DP thymocyte toxicity (93). In such a
model, decreased cytokine production by peripheral mIkB-a
T cells in response to a-CD3 treatment could account for
the decreased DP thymocyte apoptosis seen in these ani-
mals. Indeed our results demonstrate decreased cytokine
production by thymocytes after TCR cross-linking (Fig.
5). However, this non–thymocyte-autonomous model is
less likely to account for the resistance to a-CD3–induced
thymocyte death seen in the mIkB-a mice because DP
thymocytes from the mIkB-a mice are also resistant to
a-CD3–mediated killing in FTOC. Thus, it would appear
more likely that NF-kB expression in DP thymocytes is di-
rectly required for a-CD3–induced apoptosis.
During the last several years, there has been considerable
interest in developing inhibitors of NF-kB for the treat-
ment of both autoimmune diseases and cancer. In the case
of cancer, such inhibitors might function to increase the
sensitivity of tumor cells to apoptotic cell death induced
both by cytokines such as TNF-a and by CTLs. In patients
with autoimmune disease, such inhibitors might function
by suppressing T cell activation in response to self-antigens.
Our finding that NF-kB can function to potentiate apop-
tosis in certain cell types and specifically in DP thymocytes
raises several potential concerns about the systemic admin-
istration of NF-kB inhibitors. First, it is possible that some
tumor cells and/or virus-infected cells, like DP thymo-
cytes, may actually demonstrate decreased apoptosis in re-
sponse to NF-kB inhibitors. Thus, it is possible that potent
NF-kB inhibitors might potentiate tumorgenesis in some
tissues and might also reduce host responses against viral
pathogens by decreasing susceptibility to apoptosis. Simi-
larly, our finding that NF-kB inhibitors protect DP thy-
mocytes from apoptosis suggests the possibility that the
administration of such inhibitors to patients with autoim-
mune diseases might result in a failure in the negative selec-
tion of some DP thymocytes, thereby potentially increasing
the generation of autoreactive T cell clones. Given these
possibilities, it will be important to carefully assess the ef-
fects of NF-kB inhibitors on the apoptotic potential of dif-
ferent human tumor and virus-infected cells and on the
negative selection of DP thymocytes before their wide-
spread use in human therapy.
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